anti cd81 (Boster Bio)
Boster Bio is a verified supplier 
Boster Bio manufactures this product 
91
Structured Review
Boster Bio
anti cd81
Anti Cd81, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd81/Anti-CD81+Antibody/pmc12856188-111-66-67
Average 91 stars, based on 11 article reviews
Anti Cd81, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd81/Anti-CD81+Antibody/pmc12856188-111-66-67
Average 91 stars, based on 11 article reviews
anti cd81 - by Bioz Stars,
2026-10
91/100 stars
Images
1) Product Images from "NsPEFs-enriched ADSCs-EVs alleviate osteoarthritis via RSPO3-mediated dual pro-chondrogenic and pro-M2 macrophage properties"
Article Title: NsPEFs-enriched ADSCs-EVs alleviate osteoarthritis via RSPO3-mediated dual pro-chondrogenic and pro-M2 macrophage properties
Journal: Bioactive Materials
doi: 10.1016/j.bioactmat.2026.01.006
Figure Legend Snippet: NsPEFs engineering boosts the production of ADSCs-EVs with superior yield and stability A. Schematic illustration of the high-efficiency extraction of extracellular vesicles (EVs) from adipose-derived stem cells (ADSCs) using nanosecond pulsed electric fields (NsPEFs). B. Representative transmission electron microscopy (TEM) images of isolated Ctrl-ADSCs-EVs and NsPEFs-ADSCs-EVs, showing characteristic cup-shaped morphology and bilayer membrane (scale bars: 150 nm and 75 nm). C. Nanoparticle tracking analysis (NTA) showing the particle size distribution of EVs (n = 3). D. Western blot (WB) analysis confirming the positive expression of EV-specific markers (CD81, CD63, TSG101) and the absence of the negative markers (Calnexin, Histone H3, LaminA/C). Quantification is shown on the right (n = 3). E. The particle concentration of EVs. F. NsPEFs stimulation significantly enhanced both yield and protein output compared to Ctrl-ADSCs-EVs. G. Zeta potential measurement indicating colloidal stability (n = 3). H. Purity assessment expressed as the particle-to-protein ratio ( × 10 9 particles/μg). I. Viability of cells post-NsPEFs-ADSCs-EVs treatment assessed by trypan blue exclusion assay (scale bar: 1.7 mm). Data are presented as mean ± SEM from at least three independent experiments. Statistical significance was determined by unpaired two-tailed Student's t-test or one-way ANOVA with Tukey's post-hoc test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001; ns: not significant.
Techniques Used: Extraction, Derivative Assay, Transmission Assay, Electron Microscopy, Isolation, Membrane, Western Blot, Expressing, Concentration Assay, Zeta Potential Analyzer, Trypan Blue Exclusion Assay, Two Tailed Test
Related Articles
Chromatin Immunoprecipitation:Article Title: β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. Article Snippet: .. The following primary antibodies were used: anti-N-OPN (Abcam, Cat. ab181440, 1:1000), anti-CD63 (Abcam, Cat. ab59479, 1:1000), anti-OPN (Boster Biotechnology, Cat. PB0589, 1:1000), anti-CD44 (Boster Biotechnology, Cat. A00052, 1:1000), anti-α-tubulin (Beijing Ray Antibody Biotech, Cat. RM2007, 1:5000), anti-fibronectin (Sigma, Cat. F3648, 1:50000), anti-α-SMA (Abcam, Cat. ab5648, 1:1000), anti-PDGFR-β (Santa Cruz, Cat. sc-374573, 1:1000), anti-Collagen I (Boster Biotechnology, Cat. BA0325, 1:1000), anti-Vimentin (Abcam, Cat. ab8978, 1:1000), anti-PCNA (Abcam, Cat. ab29; 1:1000), anti-active-β-catenin (Cell Signaling, Cat. #4270s, 1:1000), anti-c-Myc (Cell Signaling, Cat. #5605s, 1:1000), and anti-Foxo4 (Cell Signaling, Cat. #9472s, 1:1000), anti-TSG101 (Abcam, Cat. Ab83; 1:1000), Transfection:Article Title: β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. Article Snippet: .. The following primary antibodies were used: anti-N-OPN (Abcam, Cat. ab181440, 1:1000), anti-CD63 (Abcam, Cat. ab59479, 1:1000), anti-OPN (Boster Biotechnology, Cat. PB0589, 1:1000), anti-CD44 (Boster Biotechnology, Cat. A00052, 1:1000), anti-α-tubulin (Beijing Ray Antibody Biotech, Cat. RM2007, 1:5000), anti-fibronectin (Sigma, Cat. F3648, 1:50000), anti-α-SMA (Abcam, Cat. ab5648, 1:1000), anti-PDGFR-β (Santa Cruz, Cat. sc-374573, 1:1000), anti-Collagen I (Boster Biotechnology, Cat. BA0325, 1:1000), anti-Vimentin (Abcam, Cat. ab8978, 1:1000), anti-PCNA (Abcam, Cat. ab29; 1:1000), anti-active-β-catenin (Cell Signaling, Cat. #4270s, 1:1000), anti-c-Myc (Cell Signaling, Cat. #5605s, 1:1000), and anti-Foxo4 (Cell Signaling, Cat. #9472s, 1:1000), anti-TSG101 (Abcam, Cat. Ab83; 1:1000), Expressing:Article Title: β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. Article Snippet: .. The following primary antibodies were used: anti-N-OPN (Abcam, Cat. ab181440, 1:1000), anti-CD63 (Abcam, Cat. ab59479, 1:1000), anti-OPN (Boster Biotechnology, Cat. PB0589, 1:1000), anti-CD44 (Boster Biotechnology, Cat. A00052, 1:1000), anti-α-tubulin (Beijing Ray Antibody Biotech, Cat. RM2007, 1:5000), anti-fibronectin (Sigma, Cat. F3648, 1:50000), anti-α-SMA (Abcam, Cat. ab5648, 1:1000), anti-PDGFR-β (Santa Cruz, Cat. sc-374573, 1:1000), anti-Collagen I (Boster Biotechnology, Cat. BA0325, 1:1000), anti-Vimentin (Abcam, Cat. ab8978, 1:1000), anti-PCNA (Abcam, Cat. ab29; 1:1000), anti-active-β-catenin (Cell Signaling, Cat. #4270s, 1:1000), anti-c-Myc (Cell Signaling, Cat. #5605s, 1:1000), and anti-Foxo4 (Cell Signaling, Cat. #9472s, 1:1000), anti-TSG101 (Abcam, Cat. Ab83; 1:1000), Plasmid Preparation:Article Title: β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. Article Snippet: .. The following primary antibodies were used: anti-N-OPN (Abcam, Cat. ab181440, 1:1000), anti-CD63 (Abcam, Cat. ab59479, 1:1000), anti-OPN (Boster Biotechnology, Cat. PB0589, 1:1000), anti-CD44 (Boster Biotechnology, Cat. A00052, 1:1000), anti-α-tubulin (Beijing Ray Antibody Biotech, Cat. RM2007, 1:5000), anti-fibronectin (Sigma, Cat. F3648, 1:50000), anti-α-SMA (Abcam, Cat. ab5648, 1:1000), anti-PDGFR-β (Santa Cruz, Cat. sc-374573, 1:1000), anti-Collagen I (Boster Biotechnology, Cat. BA0325, 1:1000), anti-Vimentin (Abcam, Cat. ab8978, 1:1000), anti-PCNA (Abcam, Cat. ab29; 1:1000), anti-active-β-catenin (Cell Signaling, Cat. #4270s, 1:1000), anti-c-Myc (Cell Signaling, Cat. #5605s, 1:1000), and anti-Foxo4 (Cell Signaling, Cat. #9472s, 1:1000), anti-TSG101 (Abcam, Cat. Ab83; 1:1000), Incubation:Article Title: Exosomes from isobavachin-modified bone marrow mesenchymal stem cells promote osteoblast proliferation and alleviate osteoporosis by targeting the miR-127-3p/KIF3B/Wnt/β-catenin pathway. Article Snippet: Background: Mesenchymal stem cell-derived exosomes (MSC-exosome), a promising cell-free strategy, show attractive applications in the treatment of osteoporosis.. Pretreatment of MSCs before application can effectively improve the therapeutic efficacy of MSC-exosomes.. Our study investigated the effects of exosomes from isobavachin (IBA)-pretreated human bone marrow-derived MSCs (hBMSCIBA-exosomes) on osteoporosis progression and further unveil the underlying molecular mechanism. |